<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02143934</url>
  </required_header>
  <id_info>
    <org_study_id>07200734</org_study_id>
    <nct_id>NCT02143934</nct_id>
  </id_info>
  <brief_title>Effect of Liver and Blood-stage Treatment on Subsequent Plasmodium Reinfection and Morbidity</brief_title>
  <official_title>Host and Parasites Factors Contributing to Risk of Plasmodium Re-infection and Morbidity in Elementary School Children in Maprik, East Sepik Province</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Papua New Guinea Institute of Medical Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Walter and Eliza Hall Institute of Medical Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Swiss Tropical &amp; Public Health Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Barcelona Centre for International Health Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Papua New Guinea Institute of Medical Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study specifically seeks to quantify the contribution of relapes to the burden of P.
      vivax infections and disease by determining on the effect of radical pre-erythrocytic and
      erythrocytic clearance on subsequent rates of Plasmodium spp. infection and disease in
      children aged 5-10 years in a treatment to re-infection study design. In order the clear
      liver-stage/blood-stages G6PD-normal children were randomised to receive Chloroquine (3 days,
      standard dose) and Coartem (3 days, standard dose) plus either i) primaquine (20 days,
      0.5mg/kg) or ii) placebo (20days). These drugs were administered over a period of 4 weeks.

      In addition to this epidemiological data, the study will assess the natural acquisition of
      cellular and humoral immune responses to P. falciparum and P. vivax, thus assisting in the
      determination of correlates of clinical immunity to P. falciparum and P. vivax in PNG
      children aged 5-10 years.

      These data will not only be essential for development of future vaccines against P. vivax and
      P falciparum but provide invaluable insight into the contribution of long-lasting
      liver-stages to the force of infection with P. vivax that will contribute towards designing
      more rational approaches to the treatment of P. vivax both in the context of case management
      and future attempts at elimination.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2009</start_date>
  <completion_date type="Actual">May 2014</completion_date>
  <primary_completion_date type="Actual">May 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to first or only Plasmodium vivax infection by light microscopy and PCR</measure>
    <time_frame>8 months post-baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to first or only clinical P. vivax episode</measure>
    <time_frame>8 months post-baseline</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to first or only P. falciparum infection by light microscopy and PCR</measure>
    <time_frame>8 months post-baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first or only P. ovale infection by light microscopy and PCR</measure>
    <time_frame>8 months post-baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first or only P. malariae infection by light microscopy and PCR</measure>
    <time_frame>8 months post-baseline</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">524</enrollment>
  <condition>Plasmodium Vivax Infection</condition>
  <condition>Plasmodium Vivax Clinical Episode</condition>
  <condition>Plasmodium Falciparum Infection</condition>
  <condition>Plasmodium Falciparum Clinical Episode</condition>
  <arm_group>
    <arm_group_label>Primaquine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Primaquine, 0.5mg/kg/day, 20 days directly observed treatment Chloroquine, 25mg/kg total dose, divided over 3 days directly observed treatment Artemether-Lumefantrine, 3 days BD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo, 20 days directly observed treatment Chloroquine, mg/kg, 3 days directly observed treatment Artemether-Lumefantrine, 3 days BD</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Primaquine</intervention_name>
    <arm_group_label>Primaquine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Sugar pills, appearance identical to Primaquine tablets</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chloroquine</intervention_name>
    <arm_group_label>Primaquine</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Artemether Lumefantrine</intervention_name>
    <arm_group_label>Primaquine</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Coartem</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  aged 5-10 years (Â±3 months)

          -  permanent residents of the area

          -  absence of history of hypersensitivity reactions to the drugs

        Exclusion Criteria:

          -  chronic illness

          -  severe malnutrition (weight-for-age nutritional Z score [WAZ] &lt;60th percentile)

          -  severe anemia (Hb &lt;5 g/dL),

          -  G-6-PD deficiency (&lt;60% G-6-PD activity)

          -  permanent disability, which prevents or impedes study participation. Any 1 or more of
             the criteria is sufficient to exclude study participation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>10 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ivo Mueller, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Walter and Eliza Hall Institute of Medical Research; Centre de Recerca en Salut Internacional de Barcelona (CRESIB)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Inoni Betuela, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>PNG Institute of Medical Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Louis Schofield, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Walter and Eliza Hall Institute of Medical Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>PNG Institute of Medical Research</name>
      <address>
        <city>Maprik</city>
        <state>East Sepik Province</state>
        <country>Papua New Guinea</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Papua New Guinea</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 19, 2014</study_first_submitted>
  <study_first_submitted_qc>May 19, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 21, 2014</study_first_posted>
  <last_update_submitted>May 19, 2014</last_update_submitted>
  <last_update_submitted_qc>May 19, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 21, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Plasmodium vivax</keyword>
  <keyword>Hypnozoites</keyword>
  <keyword>Primaquine</keyword>
  <keyword>Liver-stage</keyword>
  <keyword>Blood-stage</keyword>
  <keyword>Plasmodium falciparum</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Malaria</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chloroquine</mesh_term>
    <mesh_term>Chloroquine diphosphate</mesh_term>
    <mesh_term>Lumefantrine</mesh_term>
    <mesh_term>Artemether</mesh_term>
    <mesh_term>Primaquine</mesh_term>
    <mesh_term>Artemether-lumefantrine combination</mesh_term>
    <mesh_term>Artemisinins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

